Curing HIV will be harder than curing cancer. Apart from a few 'miracle' cases, antiretrovirals only suppress HIV, they don't ...

HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...

首个专门针对清除潜伏HIV-1细胞的T细胞受体（TCR）疗法已经通过了初步临床试验。这种双特异性免疫疗法可以靶向并清除那些长期携带HIV的CD4+细胞，也就是所谓的“病毒储存库”。

第一个成功的治愈案例是蒂莫西·雷·布朗，被称为“柏林患者”。2006年，他因急性髓性白血病接受了两次干细胞移植。柏林查理特医院的肿瘤学专家Gero Hütter博士提出使用带有CCR5-delta32突变的供体干细胞，这种突变可以阻止大多数HIV病毒进入细胞。

Stanford researchers highlight the potential of EBC-46, a compound derived from Australia’s blushwood tree, in eradicating ...

today announced the opening of the ACACIA study (Antiretrovirals Combined with Antibodies for HIV-1 Cure in Africa), also ...

A new chemical compound has been making a big impression in the fight against cancer in recent years. Now it seems EBC-46, otherwise known as tigilanol tiglate, may also have immense potential for ...

Local AIDS experts are at odds with the United Nations Programme on HIV/AIDS (UNAIDS) over its claims that AIDS could be ...

A move by the Trump administration to freeze funding for PEPFAR, the widely heralded international HIV/AIDS program, is ...

A unique reaction in which antibodies bind to other antibodies may help scientists at Scripps Research better understand how ...

A series of orders from the Trump administration have the potential to disrupt the delivery of life-saving medications to HIV ...

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter. HB-500 ...